Chargement en cours...
Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
The advent of sodium-glucose cotransporter 2 (SGLT2) inhibitors represents a major advance for people with type 2 diabetes (T2DM) and chronic kidney disease (CKD). The results of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial have cle...
Enregistré dans:
| Publié dans: | Nephrol Dial Transplant |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993192/ https://ncbi.nlm.nih.gov/pubmed/32003833 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfz252 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|